Allarity Therapeutics updates stenoparib manufacturing on track for Q3 2026

Allarity Therapeutics, Inc.

API manufacturing campaign on track for completion no later than Q3 2026 at GMP-compliant CDMO.
All manufacturing payments completed; no additional cash outlays anticipated.
Supports potential pivotal trial in advanced ovarian cancer following FDA Fast Track designation.
Ongoing Phase 2 trial in advanced ovarian cancer continues enrolling under amended protocol.
Phase 2 trial of stenoparib + temozolomide for relapsed SCLC recruiting across multiple VA sites.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.